This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cordis Corporation Announces One-Year Results From The STROLL Trial

Stocks in this article: JNJ

Cordis Corporation today announced the presentation of the STROLL study results at the Late Breaking Clinical Trials session at VIVA 2012.

Michael R. Jaff, DO, presented the results of the STROLL study ( S.M.A.R.T. ® Nitinol Self-Expanding Stent in the TReatment of Obstructive Superficia L Femora L Artery Disease) on behalf of the study investigators. The STROLL study assessed the safety and efficacy of the S.M.A.R.T.® Nitinol Self-Expandable Stent System (S.M.A.R.T.® Stent) in treating patients with obstructive superficial femoral artery (SFA) disease.

“The STROLL trial demonstrates one year patency rates of ~81% and a very low fracture rate,” said Dr. William A. Gray, Director of Endovascular Services, Cardiovascular Research Foundation, New York. “These outcomes both meet and exceed our expectations for patients with symptomatic disease of the superficial femoral artery.”

In the study, the average lesion length was 77 mm, 23.6% of patients presented with total occlusions and 47% of patients were diabetic. Freedom from clinically driven target lesion revascularization (TLR) at one year was 87.4%. The 12-month primary patency rate for the S.M.A.R.T.® Stent was 81.7% by Kaplan Meier estimate. The primary duplex patency rate (PSVR>/=2.5) was 81.1%. There were no major adverse events at 30 days after the initial index procedure. There was also a low rate of stent fractures noted at 12 months (1.8%). All stent fractures were Type I, least severe, there were no incidents of more severe stent fractures (Type II-V).

“We are very pleased with the results of the STROLL study,” said Shlomi Nachman, Worldwide President, Cordis Corporation, “As it achieved the protocol’s prospective primary safety and efficacy endpoints for the S.M.A.R.T.® Stent in the treatment of peripheral artery disease.”

STROLL is a multicenter, non-randomized, single-arm, prospective trial comparing efficacy and safety of the S.M.A.R.T.® Stent with a previously published objective performance goal. Patients ≥30 years of age with de novo or restenotic native SFA lesion(s) or total occlusions with length ≥ 4.0 cm to ≤ 15.0 cm, and reference vessel diameters of ≥ 4.0 mm to ≤ 6.0 mm were included in the study. The 12-month primary patency endpoint was defined as no relevant flow reduction by duplex ultrasonography (DUS) determined by independent core lab, and no interim clinically driven TLR. The primary safety endpoint was 30-day freedom from major adverse events, a composite of all-cause death, index limb amputation and clinically driven TLR. Secondary endpoints cover a variety of morphological, clinical and hemodynamic outcomes.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,974.31 -31.44 -0.18%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,549.2260 -15.0680 -0.33%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs